Immunicum reports positive phase I/II-data for the therapeutic cancer vaccine INTUVAX® in the treatment of kidney cancer 5 December 2013 Read more
Immunicum reports positive phase I/II-data for the therapeutic cancer vaccine INTUVAX® in the treatment of kidney cancer 5 December 2013 Read more
Immunicum’s patent application regarding the Company’s core-technology for therapeutic cancer vaccination using allogeneic dendritic cells is being approved in the U.S. 25 October 2013 Read more
Immunicum's patent application regarding the Company's core-technology for therapeutic cancer vaccination using allogeneic dendritic cells is being approved in the U.S. 25 October 2013 Read more
Immunicum doses the first patient in a new clinical phase I/II-study in primary liver cancer 23 October 2013 Read more
Immunicum doses the first patient in a new clinical phase I/II-study in primary liver cancer 23 October 2013 Read more
The Regional Ethical Review Board approves start of Immunicum’s planned liver cancer vaccine study 21 August 2013 Read more
The Regional Ethical Review Board approves start of Immunicum's planned liver cancer vaccine study 21 August 2013 Read more
Faster pace than expected, Immunicum completes treatment of the last patient in its kidney cancer vaccine phase I/II-study already in August 19 August 2013 Read more
Faster pace than expected, Immunicum completes treatment of the last patient in its kidney cancer vaccine phase I/II-study already in August 19 August 2013 Read more
The Medical Products Agency clears unique Swedish cancer vaccine for clinical tests in liver cancer patients 22 July 2013 Read more
The Medical Products Agency clears unique Swedish cancer vaccine for clinical tests in liver cancer patients 22 July 2013 Read more
Promising data for cancer vaccine INTUVAX(TM) in the treatment of kidney cancer 20 May 2013 Read more
Immunicum AB (publ) issues new shares before listing on NASDAQ OMX First North 4 March 2013 Read more
Immunicum AB (publ) issues new shares before listing on NASDAQ OMX First North 4 March 2013 Read more
